The 100,000 Genomes Project ran between 2014 and 2018. It was established to sequence 100,000 genomes from more than 85,000 NHS patients affected by a rare disease or cancer, to help doctors better understand, and ultimately treat, rare and inherited diseases and various cancers.
Recruitment of participants to the 100,000 Genomes Project was completed in 2018, with the 100,000th sequence achieved in December 2018.
The primary results have been analysed and all reports were issued to referring clinicians by summer 2020. If you are a participant in the project and have not received your primary results, please contact your clinical team.
As part of participants’ consent for the 100,000 Genomes Project, they were asked if they wanted Genomics England to look for additional health information in their genome sequence, not related to the condition for which they were recruited to the Project.
These additional findings are now being analysed. It is anticipated that results will be returned to those participants who consented to receive them between summer 2021 and spring 2022. Participants who wish to check whether they consented for additional findings or to change their choice can do this through the Check My Choice portal. Further information on additional findings, and links to the Check My Choice portal can be found on the Genomics England website.
In late 2012, Former Prime Minister David Cameron, announced the 100,000 Genomes Project. The project built on exciting discoveries about the genetic code of human beings, advances in the speed and cost at which the human genome could be sequenced, and the potential for genomics to be introduced into mainstream healthcare.
Genomics England, a company wholly owned and funded by the Department of Health & Social Care, was set up to deliver the project and sequence 100,000 whole genomes from NHS patients.
The four main aims of the project were to;
- create an ethical and transparent programme based on consent;
- bring benefit to patients and pave the way for a genomic medicine service in the NHS;
- enable new scientific discovery and medical insights to improve and develop personalised treatments;
- and kick start the development of a UK genomics industry.
People were recruited to the 100,000 Genomes Project through NHS Genomic Medicine Centres, which were created to work with the NHS genetic and other specialist services in their area to coordinate recruitment, testing and sharing of results. The North Thames NHS Genomic Medicine Centre, led by Great Ormond Street Hospital NHS Foundation Trust, and the West London Genomic Medicine Centre, led by Imperial College Healthcare NHS Trust were responsible for recruitment within the North Thames GLH region.
Why cancer and rare diseases
The 100,000 Genomes project focused on patients with a rare and inherited disease and their families, and patients with cancer. Genomics has great potential for both cancer and rare diseases as they are both strongly linked to changes in the genome.
In the UK, just fewer than 160,000 people died from cancer in 2011, with over 330,000 new cases reported every year.
Cancer begins because of changes in genes within what was a normal cell. By taking DNA from the tumour and DNA from the patient’s normal cells and comparing them, the precise changes may be detected. Knowing and understanding these can sometimes help determine which treatments will be the most effective
Rare and inherited diseases
1 in 17 people in the UK – around 3 million people – are affected by a rare disease.
At least 80 percent of rare diseases are caused by genetic changes, and half of new cases are found in children. Understanding the changes in the genome of people with rare diseases may identify the cause of some rare diseases and help point the way to new treatments for these conditions.
The 100,000 Genomes Project paved the way for a new Genomic Medicine Service (GMS) for the NHS – transforming patient care and enabling equity of access to advanced diagnosis and personalised treatments across England.
The project has also generated a wealth of data for researchers and acted as a kick-starter for the UK genomics industry. Through combining genomic sequence data with medical records, researchers are being able to make progress in understanding the causes, diagnosis and treatment of disease.
(Source: Genomics England)